【甘李药业胰岛素周制剂GZR4注射液中国2型糖尿病III期临床研究SUPER-2完成首例受试者给药】 甘李药业股份有限公司宣布公司自主研发的基础胰岛素周制剂GZR4注射液在中国既往接受过基础胰岛素治疗的2型糖尿病受试者中的开展的一项大规模III期临床研究完成首例受试者给药,这也是甘李药业启动的GZR4注射液全球首项III期临床研究。

金融界
15 Feb
甘李药业股份有限公司宣布公司自主研发的基础胰岛素周制剂GZR4注射液在中国既往接受过基础胰岛素治疗的2型糖尿病受试者中的开展的一项大规模III期临床研究完成首例受试者给药,这也是甘李药业启动的GZR4注射液全球首项III期临床研究。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10